The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids

Objectives: To describe benzodiazepine and prescription opioid use by clients of drug treatment services and the sources of pharmaceuticals they use. Design: Structured face-to-face interviews on unsanctioned use of benzodiazepines and prescription opioids were conducted between January and July 200...

Full description

Bibliographic Details
Main Authors: Nielsen, S., Bruno, R., Degenhardt, L., Stoove, M., Fischer, J., Carruthers, Susan, Lintzeris, N.
Format: Journal Article
Published: Australasian Medical Publishing Company Pty. Ltd. 2013
Online Access:http://hdl.handle.net/20.500.11937/35021
_version_ 1848754382544306176
author Nielsen, S.
Bruno, R.
Degenhardt, L.
Stoove, M.
Fischer, J.
Carruthers, Susan
Lintzeris, N.
author_facet Nielsen, S.
Bruno, R.
Degenhardt, L.
Stoove, M.
Fischer, J.
Carruthers, Susan
Lintzeris, N.
author_sort Nielsen, S.
building Curtin Institutional Repository
collection Online Access
description Objectives: To describe benzodiazepine and prescription opioid use by clients of drug treatment services and the sources of pharmaceuticals they use. Design: Structured face-to-face interviews on unsanctioned use of benzodiazepines and prescription opioids were conducted between January and July 2008.Participants: Convenience sample of treatment entrants who reported regular(an average of 4 days per week) and unsanctioned use of benzodiazepines and/or prescription opioids over the 4 weeks before treatment entry. Setting: Drug treatment services in Victoria, Queensland, Western Australia and Tasmania. Main outcome measures: Participant demographics, characteristics of recent substance use, substance use trajectories, and sources of pharmaceuticals. Results: Two hundred and four treatment entrants were interviewed. Prescription opioids were predominantly obtained from non-prescribed sources (78%, 84/108). In contrast, medical practitioners were the main source for benzodiazepines (78%, 113/144). Forging of prescriptions was extremely uncommon. A mean duration of 6.3 years (SD, 6.6 years) for benzodiazepines and 4.4 years (SD, 5.7 years) for prescription opioids was reported between first use and problematic use — a substantial window for intervention. Conclusions: Medical practitioners are an important source of misused pharmaceuticals, but they are not the main source of prescription opioids. This has implications for prescription drug monitoring in Australia: current plans (to monitor only Schedule 8 benzodiazepines and prescription opioids) may have limited effects on prescription opioid users who use non-prescribed sources, and the omission of most benzodiazepines from monitoring programs may represent a lost opportunity for reducing unsanctioned use of benzodiazepines and associated harm.
first_indexed 2025-11-14T08:39:31Z
format Journal Article
id curtin-20.500.11937-35021
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:39:31Z
publishDate 2013
publisher Australasian Medical Publishing Company Pty. Ltd.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-350212017-09-13T15:29:11Z The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids Nielsen, S. Bruno, R. Degenhardt, L. Stoove, M. Fischer, J. Carruthers, Susan Lintzeris, N. Objectives: To describe benzodiazepine and prescription opioid use by clients of drug treatment services and the sources of pharmaceuticals they use. Design: Structured face-to-face interviews on unsanctioned use of benzodiazepines and prescription opioids were conducted between January and July 2008.Participants: Convenience sample of treatment entrants who reported regular(an average of 4 days per week) and unsanctioned use of benzodiazepines and/or prescription opioids over the 4 weeks before treatment entry. Setting: Drug treatment services in Victoria, Queensland, Western Australia and Tasmania. Main outcome measures: Participant demographics, characteristics of recent substance use, substance use trajectories, and sources of pharmaceuticals. Results: Two hundred and four treatment entrants were interviewed. Prescription opioids were predominantly obtained from non-prescribed sources (78%, 84/108). In contrast, medical practitioners were the main source for benzodiazepines (78%, 113/144). Forging of prescriptions was extremely uncommon. A mean duration of 6.3 years (SD, 6.6 years) for benzodiazepines and 4.4 years (SD, 5.7 years) for prescription opioids was reported between first use and problematic use — a substantial window for intervention. Conclusions: Medical practitioners are an important source of misused pharmaceuticals, but they are not the main source of prescription opioids. This has implications for prescription drug monitoring in Australia: current plans (to monitor only Schedule 8 benzodiazepines and prescription opioids) may have limited effects on prescription opioid users who use non-prescribed sources, and the omission of most benzodiazepines from monitoring programs may represent a lost opportunity for reducing unsanctioned use of benzodiazepines and associated harm. 2013 Journal Article http://hdl.handle.net/20.500.11937/35021 10.5694/mja13.11331 Australasian Medical Publishing Company Pty. Ltd. restricted
spellingShingle Nielsen, S.
Bruno, R.
Degenhardt, L.
Stoove, M.
Fischer, J.
Carruthers, Susan
Lintzeris, N.
The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title_full The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title_fullStr The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title_full_unstemmed The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title_short The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
title_sort sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
url http://hdl.handle.net/20.500.11937/35021